tailieunhanh - Báo cáo y học: "Aberrant glycosylation associated with enzymes as cancer biomarkers"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Aberrant glycosylation associated with enzymes as cancer biomarkers. | Meany and Chan Clinical Proteomics 2011 8 7 http content 8 1 7 CLINICAL PROTEOMICS REVIEW Open Access Aberrant glycosylation associated with enzymes as cancer biomarkers Danni L Meany and Daniel W Chan Correspondence dmeany1@jhmi. edu Department of Pathology Johns Hopkins University Baltimore MD 21231 USA 2 BioMed Central Abstract Background One of the new roles for enzymes in personalized medicine builds on a rational approach to cancer biomarker discovery using enzyme-associated aberrant glycosylation. A hallmark of cancer aberrant glycosylation is associated with differential expressions of enzymes such as glycosyltransferase and glycosidases. The aberrant expressions of the enzymes in turn cause cancer cells to produce glycoproteins with specific cancer-associated aberrations in glycan structures. Content In this review we provide examples of cancer biomarker discovery using aberrant glycosylation in three areas. First changes in glycosylation machinery such as glycosyltransferases glycosidases could be used as cancer biomarkers. Second most of the clinically useful cancer biomarkers are glycoproteins. Discovery of specific cancer-associated aberrations in glycan structures of these existing biomarkers could improve their cancer specificity such as the discovery of AFP-L3 fucosylated glycoforms of AFP. Third cancer-associated aberrations in glycan structures provide a compelling rationale for discovering new biomarkers using glycomic and glycoproteomic technologies. Summary As a hallmark of cancer aberrant glycosylation allows for the rational design of biomarker discovery efforts. But more important we need to translate these biomarkers from discovery to clinical diagnostics using good strategies such as the lessons learned from translating the biomarkers discovered using proteomic technologies to OVA 1 the first FDA-cleared In Vitro Diagnostic Multivariate Index Assay IVDMIA . These lessons providing important guidance in .